Novo Nordisk, maker of weight-loss drug Wegovy, struck a deal with online telehealth storefronts that sold cheap knockoffs during shortages.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
The company plans to have one of the newfangled small modular reactors up and running in Wyoming by 2030.
Why is Saudi Arabia spending a king’s ransom on sports? The Middle East powerhouse doesn’t care if you call it sportswashing.
The energy titan has extended the timeline for its plan to reduce its “carbon intensity.”
Reducing beverage-wait times is part of Starbucks CEO Brian Niccol’s turnaround plan, which includes tech updates focused on efficiency.
An insurance nonprofit found that claims about autonomous driving safety don’t measure up.
Southwest and Alaska said that the manufacturer’s uncertain status makes it hard to forecast the year ahead.
The vacation rental company is ramping up privacy as it continues to battle customer satisfaction issues.
To prepare for a slowdown of global trade, US retailers spent months building a massive inventory to prevent empty shelves.
Temu is now one of the biggest ad clients for both Google and Meta, according to The Wall Street Journal and The New York Times.
Novo Nordisk has announced a new drug in its pipeline performed much better than Wegovy in helping participants to lose weight.
The future of the connected car may come with a lot of driver data collection for the sake of personalization.
Canada’s Liberal Party won a majority promising to distance the country from the US, a major importer of Canadian crude.
Investor worries about a fresh batch of US tariffs have dragged LVMH shares in Paris down 23.6% so far this year.
The company plans to seek regulatory approval for the revolutionary weight loss treatment by the end of the year.
The warnings come as the industry adapts to seismic shifts in technology — which means it may just have some new tricks up its sleeve.